Develops oral antiviral drug candidates for hepatitis C and hepatitis E infections.
10-K for FY2025, filed Mar 5, 2026
10-Q for Q3 FY2026, filed Nov 9, 2026
−$32.2MView ↗
From coronavirus to hepatitis
The older report centered on bemnifosbuvir for coronavirus disease. The latest report focuses on hepatitis C and hepatitis E candidates and says the company stopped developing bemnifosbuvir for coronavirus disease after its trial missed its primary endpoint.
10-K for FY2022, filed Feb 28, 2023 10-K for FY2025, filed Mar 5, 2026We are a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve…View ↗
We are a late-stage clinical biopharmaceutical company leveraging our deep understanding of antiviral drug development, medicinal…View ↗
We are developing AT-587 for the treatment of chronic HEV infection in immunocompromised patients. In this high-risk patient population…View ↗
In addition, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown obstacles in developing…View ↗
Competes with Gilead Sciences, AbbVie, and Merck
10-K for FY2025, filed Mar 5, 2026Sovaldi® (sofosbuvir) (Gilead Sciences, Inc.), an HCV nucleotide analog NS5B polymerase inhibitor approved for the treatment of adult…View ↗
Loading...